Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for several of its drugs? The drugmaker raised its full-year 2017 guidance three months ago, banking on that impact being less than initially feared.
Valeant answered this question when the company reported on its second-quarter performance before the market opened on Tuesday. The bigger story, though, related to its debt-reduction efforts. Here are the highlights from Valeant's update.
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Stock
€5.68
-0.710%
